Carsten GrÃ¼llich

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3728489/publications.pdf

Version: 2024-02-01

21	324	840776 11	888059 17
papers	citations	h-index	g-index

21	21	21	697
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Couples coping with advanced prostate cancer: An explorative study on treatment decision making, mental deterioration, partnership, and psychological burden. Urologic Oncology: Seminars and Original Investigations, 2021, , .	1.6	3
2	Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a populationâ€based study. Molecular Oncology, 2020, 14, 363-372.	4.6	23
3	Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3189-3198.	2.5	22
4	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ¯ve metastatic prostate cancer â€“Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	1.6	12
5	Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. Cancer Immunology, Immunotherapy, 2019, 68, 2005-2014.	4.2	24
6	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget, 2019, 10, 17-29.	1.8	21
7	Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. Oncology Letters, 2019, 17, 3890-3898.	1.8	13
8	Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL. Future Science OA, 2018, 4, FSO299.	1.9	3
9	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, 2018, 8, 16708.	3.3	27
10	Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. British Journal of Cancer, 2018, 119, 170-175.	6.4	6
11	Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. Oncotarget, 2018, 9, 22537-22545.	1.8	4
12	Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. European Journal of Cancer, 2017, 76, 1-7.	2.8	49
13	The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. Future Oncology, 2017, 13, 1463-1471.	2.4	3
14	Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. Journal of Cancer, 2017, 8, 507-512.	2.5	2
15	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget, 2017, 8, 74049-74057.	1.8	14
16	MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget, 2017, 8, 1046-1057.	1.8	26
17	Local salvage therapy for late (â‰¥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 238.e9-238.e17.	1.6	7
18	Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. Journal of Neuro-Oncology, 2016, 130, 221-228.	2.9	26

#	Article	IF	Citations
19	Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 433.e1-433.e8.	1.6	21
20	Features of cell death, mitochondrial activation and caspase dependence of rabbit anti-T-lymphocyte globulin signaling in lymphoblastic Jurkat cells are distinct from classical apoptosis signaling of CD95. Leukemia and Lymphoma, 2016, 57, 177-182.	1.3	2
21	Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. Clinical Genitourinary Cancer, 2015, 13, e145-e152.	1.9	16